Bladder cancer is a common diagnosis, affecting 70,000 Americans each year.
Because the diagnosis, management, and long-term follow-up of non-muscle invasive bladder cancer requires advanced imaging and invasive testing, economic evaluations have shown bladder cancer to be the costliest cancer to treat in the US on a per capita basis. Adjunctive tests for surveillance have not obviated the need for cystoscopy and cytology. Indirect costs to patients include loss of work, decreased productivity, and diminished quality of life associated with diagnosis, treatment, and surveillance. Improved value may be achieved with better compliance with evidence-based practices for non-muscle invasive bladder cancer care.
Written by:
James AC, Gore JL. Are you the author?
Department of Urology, University of Washington, 1959 Northeast Pacific Street, Box 356510, Seattle, WA 98195, USA.
Reference: Urol Clin North Am. 2013 May;40(2):261-9.
doi: 10.1016/j.ucl.2013.01.004
PubMed Abstract
PMID: 23540783
UroToday.com Bladder Cancer Section
